Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Receives $16.00 Consensus Target Price from Analysts

Shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) have received an average rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $16.00.

A number of equities analysts recently weighed in on NTHI shares. Alliance Global Partners assumed coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price for the company. Wall Street Zen downgraded Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Finally, BTIG Research restated a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research note on Tuesday, September 8th.

Insider Transactions at Neonc Technologies

In other Neonc Technologies news, CEO Amir F. Heshmatpour bought 37,000 shares of the stock in a transaction dated Friday, September 11th. The shares were bought at an average cost of $3.67 per share, for a total transaction of $135,790.00. Following the purchase, the chief executive officer directly owned 3,133,000 shares of the company’s stock, valued at approximately $11,498,110. This trade represents a 1.20% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas C. Chen acquired 12,757 shares of the stock in a transaction on Tuesday, August 18th. The stock was bought at an average cost of $5.49 per share, for a total transaction of $70,035.93. Following the transaction, the chief executive officer owned 13,705 shares of the company’s stock, valued at approximately $75,240.45. This trade represents a 1,345.68% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 134,812 shares of company stock worth $530,149 over the last three months.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its position in shares of Neonc Technologies by 5.0% during the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after buying an additional 11,108 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in Neonc Technologies during the second quarter valued at about $126,000. Westmount Partners LLC lifted its position in Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after purchasing an additional 153,858 shares during the last quarter. BlackRock Inc. bought a new stake in Neonc Technologies in the 2nd quarter worth $815,000. Finally, HighPoint Advisor Group LLC grew its stake in shares of Neonc Technologies by 20.5% in the fourth quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock worth $9,466,000 after purchasing an additional 194,408 shares during the last quarter.

Neonc Technologies Trading Down 12.4%

NASDAQ NTHI opened at $3.31 on Wednesday. The business’s 50-day moving average price is $4.04 and its two-hundred day moving average price is $5.27. Neonc Technologies has a 12 month low of $3.01 and a 12 month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Trending Headlines about Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.